Journal
JOURNAL OF IMMUNOLOGY
Volume 189, Issue 5, Pages 2151-2158Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1103741
Keywords
-
Categories
Funding
- National Institutes of Health Grant [AI053825, CA158823]
- National Institutes of Health Institutional Postdoctoral Training Award [AI049823]
- Trudeau Institute
Ask authors/readers for more resources
Dendritic cells (DCs) are potent inducers of T cell immunity, and autologous DC vaccination holds promise for the treatment of cancers and chronic infectious diseases. In practice, however, therapeutic vaccines of this type have had mixed success. In this article, we show that brief exposure to inhibitors of mechanistic target of rapamycin (mTOR) in DCs during the period that they are responding to TLR agonists makes them particularly potent activators of naive CD8(+) T cells and able to enhance control of B16 melanoma in a therapeutic autologous vaccination model in the mouse. The improved performance of DCs in which mTOR has been inhibited is correlated with an extended life span after activation and prolonged, increased expression of costimulatory molecules. Therapeutic autologous vaccination with DCs treated with TLR agonists plus the mTOR inhibitor rapamycin results in improved generation of Ag-specific CD8(+) T cells in vivo and improved antitumor immunity compared with that observed with DCs treated with TLR agonists alone. These findings define mTOR as a molecular target for augmenting DC survival and activation, and document a novel pharmacologic approach for enhancing the efficacy of therapeutic autologous DC vaccination. The Journal of Immunology, 2012, 189: 2151-2158.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available